In an ACT model using the murine BRAFV600E mutant melanoma SM1 and transgenic T cells recognizing gp100 and ovalbumin (OVA), combined ACT and vemurafenib induced superior anti-SM1 tumor immune responses compared to either of the therapies alone. This evidence concerns the gene PMEL and melanoma.